Skip to main content

Table 1 Characteristics of the study population (n = 275)

From: Progression of liver stiffness predicts clinical events in HIV/HCV-coinfected patients with compensated cirrhosis

Parameter

Value

Age (years)a

44 (42–48)

Male gender, no. (%)

245 (89)

Daily alcohol intake > 50 grs/day, no. (%)

40 (14)

Previous intravenous drug users, no. (%)

250 (91)

Previous therapy against HCV, no (%)

57 (21)

HCV genotype, no. (%)b

 

 1

165 (61)

 2

2 (1)

 3

61 (23)

 4

41 (15)

HCV RNA load (log10 IU/mL)a,c

6.17 (5.68–6.69)

Positive hepatitis B virus surface antigen, no (%)

8 (3)

Serum alanine aminotransferase (IU/L)a

74 (48–105)

Serum aspartate aminotransferase (IU/L)a

72 (47–104)

Total bilirrubin (mg/dL)a

0.7 (0.5–1.02)

Platelet count (/mm3)a

130000 (94000–171750)

HIV RNA load < 50 copies/mL, no. (%)

184 (67)

CD4 cells/mLa

459 (265–626)

ARTd, no (%)

256 (83)

MELDe scorea,f

7 (6–9)

Child-Turcotte-Pugh class, no (%)

 

 A

248 (90)

 B

27 (10)

Liver stiffness (kPa)a

20 (17–27)

  1. aMedian (Q1-Q3)
  2. Available in b269 and
  3. c254 patients
  4. dART: Antiretroviral therapy
  5. eMELD: Model for end-stage liver disease
  6. fAvailable in 251 patients